(01:07)
 Has the utility or the role of antibody testing changed or evolved in any way for you over the past months or since the pandemic began?

(04:06)
 What do we know about the antibody response to the virus and how is our knowledge grown in that area? I think one question that people have is do we all make antibodies to the virus and how long do those antibodies last, and will they protect us from re-infection?

(06:41)
 You mentioned briefly there's a neutralizing antibody test that recently received FDA emergency use authorization. Can you tell us a little bit about that and how you envision that test being used?

(10:33)
 Can we reach herd immunity based on natural infection alone?

(11:56)
 Once we have a vaccine, do you envision antibody testing being used to confirm that vaccination was successful? That people develop an antibody response because of the vaccine?

(14:10)
 And would you say, out of all the antibody tests, how many of them are spike — that detect antibodies to the spike protein? It's all of them, right?

Resources
COVID-19 Testing Resource Center

The Importance of Antibody Testing in Addressing COVID-19

COVID-19 Testing

Frequently Asked Questions: COVID-19 Serology Testing
 
 

(00:41)
 Dr. Bornhorst, could you provide our listeners with a little bit about you and your background?
 

(01:15)
 Can you provide a brief overview of the alpha-gal galactose-alpha 1,3 galactose assay?
 
 (04:19)
 So I understand that most people obtain this allergy primarily from ticks and meat-derived products, and that it can cause symptoms such as hives, itching, difficulty breathing, and other unpleasant reactions. With that being said, can you tell us which patients should have this testing?
 
 (06:11)
 Do you know if there are other testing options available?
 
 (07:17)
 Can you share what factors determine which tests should be used and when? 
 
 

(00:47)
 Can you tell us a little bit about yourself and how your role has changed since COVID-19?

(02:02)
 How do you feel that testing will help Mayo and hospitals respond to this coming season's challenge?

(03:38)
 Can you tell us a little bit about the algorithm and how it helps to address perhaps potential resource shortages, knowing that we probably can't test everyone for everything all the time, and that may not be the best approach anyway?

(05:50)
 In your mind, what significance does it have if there's a positive or a negative result from the different tests that we'll be doing in the algorithm for SARS-CoV-2, influenza and RSV?

(08:18)
 But what about SARS-CoV-2 and influenza? Were you able to break that down at all for directing testing?

(09:01)
 The symptoms for influenza and COVID-19 are so similar, would it be appropriate to say that any symptomatic patient you would recommend testing for both at the same time, but RSV testing would only be added on to that algorithm for the patients that are at specific risk for RSV disease, like our young kids and our immunocompromised folks?

(09:51)
 So in using a triage system, would there be some patients that would go down the branches of the algorithm for testing versus those that wouldn't require testing?

(10:21)
 So out of all of this, what lessons have you learned that other health care professionals would benefit from?

(11:13)
 Have you seen anything inspiring that you've noticed during the pandemic?

(12:29)
 Is there anything else that you'd like to share with our audience today?

Resources
COVID-19 Testing Resource Center

COVID-19 & influenza testing algorithm arms Mayo Clinic for the upcoming flu season

Experts from Mayo Clinic featured in CAP Today

(00:45)
 Could you just provide our listeners with a little bit of information about you and your background?
 
 (01:00)
 The laboratory recently made some updates to this testing for minimal residual disease. Can you just give us a brief overview of that assay?

(03:22)
 So these patients go through these treatments, and at what point do they really need this testing, or when should it be considered by clinicians to perform it?

(05:18)
 What brought the laboratory to flow cytometry for this MRD test for this particular disease state? Why did we not choose those other methods?

(09:44)
 So hearing you talk about how this test is serving the entire patient population, how are these results for this minimal residual disease test used for patient care?
 

Resources:
https://www.cdc.gov/coronavirus/2019-ncov/community/large-events/considerations-for-events-gatherings.html

Speaker 1: (00:39)
 Can you start by sharing a little bit about yourself and your expertise for our listeners?
 
 

Speaker 1: (01:12)
 We're in this pandemic with COVID-19, and I'm hearing about people having hematologic responses to COVID-19. Can you tell us a little bit about what these responses are?

Speaker 2: (04:53)
 Here at Mayo Clinic, do we have an assay or a testing profile that could assist physicians who are dealing with COVID-19 and their patients and help them look at how their patients are doing?

Speaker 2: (07:09)
 Why is this testing important and would it affect COVID-19 patient management?

Speaker 2: (08:49)
 What challenges have you encountered during this pandemic and how have you overcome them?

Speaker 2: (10:04)
 Is there anything you've seen that you found has been particularly inspiring during the pandemic?

Speaker 2: (12:18)
 Is there anything else that you'd like to share with our audience?